Domainex has revealed human ex vivo data indicating that DMXD-011 could be effective in treating interferonopathies such as lupus, Sjögren’s syndrome, and scleroderma.
The drug candidate is an inhibitor of protein kinases TBK1 and IKK-epsilon, which previous studies suggest should be highly-effective in the treatment of inflammatory diseases.
The efficacy of DMXD-011 has already been shown in animal models of lupus and rheumatoid arthritis, without any evidence of side effects or toxicity.
The new ex vivo laboratory studies used blood samples taken from hospital patients suffering from a variety of interferonopathies and were carried out in collaboration with Dr Marjan Versnel of the Erasmus University Medical Center in Rotterdam. DMXD-011 showed a strong dose-dependent reduction in the expression of inflammatory biomarkers.
AstraZeneca has reported a similar effect in studies of its type 1 interferon receptor antibody anifrolumab using the same biomarkers.